KalVista Pharmaceuticals’ (KALV) Buy Rating Reaffirmed at HC Wainwright

KalVista Pharmaceuticals (NASDAQ:KALV)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $20.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 55.40% from the stock’s current price.

Several other equities research analysts have also commented on KALV. Needham & Company LLC dropped their price objective on shares of KalVista Pharmaceuticals from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday, July 12th. Cantor Fitzgerald raised KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 26th.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $12.87 on Friday. KalVista Pharmaceuticals has a 52-week low of $7.21 and a 52-week high of $16.88. The firm has a market capitalization of $542.96 million, a P/E ratio of -3.79 and a beta of 0.91. The stock has a 50 day moving average price of $13.16 and a 200-day moving average price of $12.43.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, July 11th. The specialty pharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.29). On average, equities analysts forecast that KalVista Pharmaceuticals will post -3.57 EPS for the current fiscal year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,135 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $12.40, for a total value of $26,474.00. Following the completion of the transaction, the insider now directly owns 83,745 shares of the company’s stock, valued at $1,038,438. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,135 shares of KalVista Pharmaceuticals stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $12.40, for a total value of $26,474.00. Following the completion of the sale, the insider now owns 83,745 shares of the company’s stock, valued at approximately $1,038,438. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Christopher Yea sold 7,102 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $12.01, for a total value of $85,295.02. Following the transaction, the insider now directly owns 84,467 shares in the company, valued at $1,014,448.67. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,452 shares of company stock valued at $282,491. 12.30% of the stock is owned by insiders.

Institutional Trading of KalVista Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. grew its position in KalVista Pharmaceuticals by 11.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock worth $44,373,000 after purchasing an additional 383,435 shares during the period. Capital World Investors bought a new stake in shares of KalVista Pharmaceuticals in the first quarter worth $17,370,000. Great Point Partners LLC purchased a new stake in KalVista Pharmaceuticals during the second quarter valued at $15,768,000. StemPoint Capital LP lifted its holdings in KalVista Pharmaceuticals by 174.4% in the first quarter. StemPoint Capital LP now owns 1,161,060 shares of the specialty pharmaceutical company’s stock valued at $13,770,000 after acquiring an additional 737,886 shares during the period. Finally, Rosalind Advisors Inc. boosted its position in KalVista Pharmaceuticals by 17.4% in the second quarter. Rosalind Advisors Inc. now owns 337,985 shares of the specialty pharmaceutical company’s stock worth $3,981,000 after purchasing an additional 50,000 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.